Business - Briefly   

Orchid receives USFDA nod

CHENNAI: Orchid Chemicals & Pharmaceuticals on Wednesday announced that it has received approval from the United States Food and Drug Administration (USFDA) for its ANDA (Abbreviated New Drug Application) of Cephalexin oral suspension. Cephalexin is an off-patent molecule that forms part of Orchid's distribution alliance with U.S.-based generic pharma major, Par Pharmaceuticals.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Cyber law to be tightened, says Maran
Infosys first quarter net up 49 p.c.
Put up your case on GATS, Govt. tells legal fraternity
Market gives thumbs down to terror, soars 316 points
HCL Infosystems launches PC for BPO/ITES sector
Murthy to continue as Chief Mentor
Coir Board signs MoU with RubberMark
SriLankan Holidays' honeymoon offer
Syndicate Bank business crosses Rs.1 lakh crores
US Technology acquires QA Labs
Franklin Templeton Investments, South Indian Bank sign MoU
Federal Bank, IDBI, Fortis to form new life insurance venture
Rupee weakens further
Pricol Tech forays into product development
National Statistical Commission comes into operation
IDFC Private Equity funding for HCG
Exchange rates
Bullion rates
Manufacturing pushes up industrial growth
MUL forms JV with Japanese firm
EU fines Microsoft
Oracle headcount to touch 10,000
Parsoli to issue shares to international firms
Essar Steel's turnover up
Orchid receives USFDA nod
Jet Airways announces tele check-in facility
SAAG RR files draft prospectus with SEBI
Euronet expands ATM deal with Centurion
SAIL bags SCOPE Gold Trophy
Sobha Renaissance acquires Munich firm
Britannia acquires strategic stake in Daily Bread
Blue Star partners Danfoss

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu